150 related articles for article (PubMed ID: 37778356)
1. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial.
Moncrieff J; Crellin N; Stansfeld J; Cooper R; Marston L; Freemantle N; Lewis G; Hunter R; Johnson S; Barnes T; Morant N; Pinfold V; Smith R; Kent L; Darton K; Long M; Horowitz M; Horne R; Vickerstaff V; Jha M; Priebe S
Lancet Psychiatry; 2023 Nov; 10(11):848-859. PubMed ID: 37778356
[TBL] [Abstract][Full Text] [Related]
2. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).
Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S
BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589
[TBL] [Abstract][Full Text] [Related]
3. Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.
Crawford MJ; Thana L; Evans R; Carne A; O'Connell L; Claringbold A; Saravanamuthu A; Case R; Munjiza J; Jayacodi S; Reilly JG; Hughes E; Hoare Z; Barrett B; Leeson VC; Paton C; Keown P; Pappa S; Green C; Barnes TR
Health Technol Assess; 2020 Sep; 24(44):1-54. PubMed ID: 32930090
[TBL] [Abstract][Full Text] [Related]
4. A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial.
Waite F; Černis E; Kabir T; Iredale E; Johns L; Maughan D; Diamond R; Seddon R; Williams N; Yu LM; Freeman D;
Lancet Psychiatry; 2023 Sep; 10(9):706-718. PubMed ID: 37562423
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
[TBL] [Abstract][Full Text] [Related]
6. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu A; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Romeo R; Gray R
Health Technol Assess; 2018 Nov; 22(67):1-62. PubMed ID: 30507375
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
[TBL] [Abstract][Full Text] [Related]
8. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
[TBL] [Abstract][Full Text] [Related]
10. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
[TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
Winter-van Rossum I; Weiser M; Galderisi S; Leucht S; Bitter I; Glenthøj B; Hasan A; Luykx J; Kupchik M; Psota G; Rocca P; Stefanis N; Teitelbaum A; Bar Haim M; Leucht C; Kemmler G; Schurr T; ; Davidson M; Kahn RS; Fleischhacker WW
Lancet Psychiatry; 2023 Mar; 10(3):197-208. PubMed ID: 36716759
[TBL] [Abstract][Full Text] [Related]
13. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
14. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.
Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE
Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.
Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu AV; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Gray R;
Lancet Psychiatry; 2018 Jul; 5(7):553-563. PubMed ID: 29880238
[TBL] [Abstract][Full Text] [Related]
16. Automated virtual reality therapy to treat agoraphobic avoidance and distress in patients with psychosis (gameChange): a multicentre, parallel-group, single-blind, randomised, controlled trial in England with mediation and moderation analyses.
Freeman D; Lambe S; Kabir T; Petit A; Rosebrock L; Yu LM; Dudley R; Chapman K; Morrison A; O'Regan E; Aynsworth C; Jones J; Murphy E; Powling R; Galal U; Grabey J; Rovira A; Martin J; Hollis C; Clark DM; Waite F;
Lancet Psychiatry; 2022 May; 9(5):375-388. PubMed ID: 35395204
[TBL] [Abstract][Full Text] [Related]
17. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis.
Ostuzzi G; Vita G; Bertolini F; Tedeschi F; De Luca B; Gastaldon C; Nosé M; Papola D; Purgato M; Del Giovane C; Correll CU; Barbui C
Lancet Psychiatry; 2022 Aug; 9(8):614-624. PubMed ID: 35753323
[TBL] [Abstract][Full Text] [Related]
18. Automated virtual reality cognitive therapy versus virtual reality mental relaxation therapy for the treatment of persistent persecutory delusions in patients with psychosis (THRIVE): a parallel-group, single-blind, randomised controlled trial in England with mediation analyses.
Freeman D; Lister R; Waite F; Galal U; Yu LM; Lambe S; Beckley A; Bold E; Jenner L; Diamond R; Kirkham M; Twivy E; Causier C; Carr L; Saidel S; Day R; Beacco A; Rovira A; Ivins A; Nah R; Slater M; Clark DM; Rosebrock L
Lancet Psychiatry; 2023 Nov; 10(11):836-847. PubMed ID: 37742702
[TBL] [Abstract][Full Text] [Related]
19. Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial.
Morant N; Long M; Jayacodi S; Cooper R; Akther-Robertson J; Stansfeld J; Horowitz M; Priebe S; Moncrieff J
EClinicalMedicine; 2023 Oct; 64():102135. PubMed ID: 37936655
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
